UK Markets open in 6 hrs 26 mins

Zynerba Pharmaceuticals, Inc. (0M40.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.9100-0.2680 (-6.41%)
At close: 5:50PM GMT
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3N/A
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7N/A

Trading information

Stock price history

Beta (5Y monthly) 2.51
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 33.9300
52-week low 33.9100
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 517.62M
Implied shares outstanding 6N/A
Float 839.13M
% held by insiders 12.60%
% held by institutions 132.24%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)31 Mar 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-33.16%
Return on equity (ttm)-58.02%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -48.92M
Net income avi to common (ttm)-46.96M
Diluted EPS (ttm)-1.5060
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)93.13M
Total cash per share (mrq)2.32
Total debt (mrq)734.47k
Total debt/equity (mrq)0.77
Current ratio (mrq)8.53
Book value per share (mrq)2.39

Cash flow statement

Operating cash flow (ttm)-38.61M
Levered free cash flow (ttm)-23.01M